Which drug you need
Different immunotherapy and targeted drugs sit at very different price points. The drug is chosen by your biomarker results, not by budget — but it is the single largest part of the cost, so knowing it early lets you plan.
Cost is one of the first worries after a lung cancer diagnosis, and it is a fair one. Immunotherapy and targeted therapy can be life-changing, but they are also among the more expensive treatments — and the real number depends on your exact drug, dose, and how long you stay on it. This page explains what shapes the immunotherapy cost for lung cancer and the targeted therapy cost, what drives the underlying lung cancer drug cost, and how CION helps you plan for it. You deserve a clear estimate, not a surprise bill.
There is no single price tag for immunotherapy cost in lung cancer, and any website that gives you one exact figure is guessing. The honest answer is that cost depends on which drug you need, the dose, and how many cycles you have — and those are decided by your cancer, not by a brochure. What we can do is explain the pieces clearly, so the final estimate makes sense rather than feeling like a shock.
Immunotherapy (immune checkpoint inhibitors) is usually given as a drip every few weeks, and for some of these drugs the dose — and therefore the cost — depends on your body weight. Targeted therapy is most often a daily tablet taken at home, matched to a specific gene change such as EGFR, ALK or ROS1. Both are ongoing treatments rather than a one-off procedure, so the cost is best thought of per cycle or per month, continuing for as long as the treatment keeps working and you tolerate it well.
The other part people forget is the lung cancer drug cost is only one line of the total. Before the drug starts, there is the cost of the biopsy and the PD-L1 and molecular tests that decide which drug fits. During treatment, there are scans to check the response, day-care infusion charges for immunotherapy, and routine blood tests. At CION, all of this is laid out before you commit — no unnecessary tests, and nothing hidden.
Most importantly, a price is only useful next to a plan. The cheapest drug is not a saving if it is the wrong one for your cancer, and the right drug becomes far more affordable once insurance, schemes and EMI are factored in. That is why we give you the cost and the medical reasoning together — see how it fits the wider plan in lung cancer treatment in Hyderabad.
Five things shape the bill more than anything else. Understanding them helps you see why two people with lung cancer can have very different costs — and where there is room to plan.
Different immunotherapy and targeted drugs sit at very different price points. The drug is chosen by your biomarker results, not by budget — but it is the single largest part of the cost, so knowing it early lets you plan.
For several immunotherapy infusions the dose depends on your weight, so the per-cycle cost varies from person to person. Targeted tablets usually have a fixed daily dose, making the monthly cost easier to predict.
These are ongoing treatments. Because they continue while they keep working, the total depends on duration. This is why cost is best understood per cycle or per month, then reviewed as treatment progresses.
Immunotherapy may be used on its own or alongside chemotherapy, depending on your PD-L1 level and cancer type. A combination usually means more line items per cycle, which your team explains in advance.
What you actually pay can be very different from the list price once cashless insurance or an eligible government scheme is applied. Our financial counsellors check your cover before you decide.
Biopsy, PD-L1 and molecular testing, and scans to check the response all add to the picture. Getting the right test once is cheaper than treating with the wrong drug — see how immunotherapy is decided.
The single most expensive mistake in lung cancer is paying for the wrong drug. Immunotherapy and targeted therapy only work when they match your tumour — so a PD-L1 and molecular test done correctly first can save the cost of months of a drug that was never going to help. This is why guidelines recommend full biomarker testing before starting treatment in advanced non-small cell lung cancer. (Source: NCCN Clinical Practice Guidelines, NSCLC.)
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
One conversation turns "how will we afford this?" into a written estimate with insurance, scheme and EMI options laid out. We walk this journey with you.
It helps to see the cost as a few separate parts rather than one number. This overview shows what each part is and what moves it up or down. Your oncologist and financial counsellor put real figures against these for your exact case — we do not quote a single fixed price online, because it would not be honest.
| Cost component | What it covers | What changes it |
|---|---|---|
| Biopsy & biomarker testing | Tissue biopsy plus PD-L1 and molecular tests (EGFR, ALK, ROS1 and others) | Which panel is needed; done once, before treatment is chosen |
| The drug itself | The immunotherapy infusion or targeted tablet — the largest single part | Which drug, the dose (weight-based for some infusions), single vs combined |
| Administration & day care | Day-care charges for immunotherapy infusions; pharmacy dispensing for tablets | Infusion vs oral; how often the cycle repeats |
| Monitoring scans | Scans to check whether the treatment is working, and routine blood tests | How often response needs to be checked; type of scan |
| Supportive care | Managing side effects, nutrition support, and any add-on care | How you tolerate treatment; usually modest compared to the drug |
| Duration | The number of cycles or months you remain on treatment | How well and how long the treatment keeps the cancer controlled |
We deliberately do not publish a single rupee figure for these drugs here, because the honest number only exists once your drug, dose and cover are known. What we promise instead is a clear written estimate, explained line by line, before you commit to anything.
A high list price is rarely what a family actually pays. Several routes can bring the real cost down a great deal — and our financial counsellors check every one with you before you decide.
Many private health policies cover cancer drug treatment, often cashless. We help you check your policy limits, pre-authorisation and what is included, so you know your real out-of-pocket figure before you start.
Schemes such as Aarogyasri, CGHS, ECHS and ESI can cover eligible patients. Cover and inclusions vary, so we check your eligibility and what applies to your treatment — we never assume or over-promise.
Because these treatments run over months, the cost can often be spread rather than paid all at once. EMI and staged-payment options can make an otherwise daunting number far more manageable for your family.
A real saving comes from not paying for what does not help. Our tumour board only recommends tests and treatments that change the plan — decisions for healing, not billing — so you are never billed for the unnecessary.
Cover, eligibility and EMI terms vary by policy and scheme, so the only reliable figure is the one worked out for your own case. Ask us to check yours — it is part of the free consultation, with no obligation to start treatment.
People often ask whether targeted therapy cost is higher or lower than immunotherapy. The truthful answer is that it depends on the specific drug, and the two are not really interchangeable — which one you can have is decided by your biomarker results, not by price. If your tumour has a targetable gene change such as EGFR, ALK or ROS1, a targeted tablet is usually the better treatment; if it does not, immunotherapy may be the option. So the cost comparison is rarely a free choice between two equal paths.
There are some practical cost differences worth knowing. Targeted therapy is usually a daily tablet taken at home, which means no day-care infusion charge and a monthly cost that is easier to predict. Immunotherapy is an infusion given in day care every few weeks, and for some drugs the dose — and therefore the cost — depends on your weight. Both continue while they keep working, so for both the total depends on how long you stay on treatment.
Rather than chase the cheaper label, the better question is which drug genuinely fits your cancer — because the wrong drug is the most expensive outcome of all. We explain both the medical fit and the cost together. See how the treatment choice is made in immunotherapy for lung cancer and how it sits alongside chemotherapy for lung cancer.
Cost worry should never be the reason a family avoids asking about treatment. At CION, you sit with a doctor for a 45-minute consultation, and a financial counsellor walks you through a clear written estimate — what the drug and tests will cost, what your insurance or scheme covers, and what EMI could look like. There are no surprise add-ons and no unnecessary tests, because our doctors are rewarded for outcomes, not billing.
Our team brings 150+ years of combined experience and 17 super-specialist oncologists across 35+ centres in Telangana and Andhra Pradesh, with a tumour board reviewing every plan. That means the drug we recommend is the one most likely to help — which is also the most cost-effective choice over time. Transparent costs are not a marketing line for us; they are part of how we believe cancer care should be done.
When you are ready, get a free written estimate, meet our lung cancer specialists in Hyderabad, or see how the whole plan comes together in lung cancer treatment in Hyderabad. You deserve to plan for treatment with clear eyes.
Patients across Telangana and Andhra Pradesh share what it felt like to have both their treatment and their costs explained honestly at CION.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.There is no single fixed price, and any site that quotes one exact figure is guessing. The cost depends mostly on which immunotherapy drug you need, the dose — which for some infusions depends on your body weight — and how many cycles you have, since these treatments continue while they keep working. On top of the drug, there is the cost of the biopsy and PD-L1 testing that decide the drug, day-care infusion charges, and scans to check the response. At CION we do not publish a single rupee figure online because it would not be honest; instead we give you a clear written estimate for your exact case, with insurance, scheme and EMI options included, before you commit.
It depends on the specific drug, and the two are not freely interchangeable — which one you can have is decided by your biomarker results, not by price. If your tumour has a targetable gene change such as EGFR, ALK or ROS1, a targeted tablet is usually the better treatment; if not, immunotherapy may be the option. There are practical cost differences: targeted therapy is often a daily tablet at home with no infusion charge and a more predictable monthly cost, while immunotherapy is an infusion given in day care, sometimes dosed by weight. The right question is not which is cheaper, but which drug actually fits your cancer, because the wrong drug is the most expensive outcome of all.
The biggest factor is which drug you need, because different immunotherapy and targeted drugs sit at very different price points. After that, the dose matters — several immunotherapy infusions are dosed by body weight, while tablets usually have a fixed daily dose. Whether immunotherapy is given alone or combined with chemotherapy changes the per-cycle cost, and the total depends on how long you stay on treatment. Finally, what you actually pay can be very different from the list price once cashless insurance or an eligible government scheme is applied. Our financial counsellors map all of these for your case before you decide.
Many private health insurance policies cover cancer drug treatment, often on a cashless basis, but cover limits, sub-limits and pre-authorisation rules vary from policy to policy. The only way to know your real out-of-pocket cost is to check your specific policy, which our team helps you do before treatment starts. We review your policy limits, what is included, and the pre-authorisation process, so there are no surprises later. We never assume cover — we confirm it with you, and explain exactly what your policy will and will not pay.
Government schemes such as Aarogyasri, CGHS, ECHS and ESI can help eligible patients, but cover and inclusions differ between schemes and not every drug or situation is covered. Because eligibility and the exact inclusions vary, we check what applies to your case rather than making a blanket promise. During your free consultation, our counsellors assess your eligibility and explain which parts of your treatment a scheme may cover and which it may not. This honest, case-by-case approach means you can plan with accurate information rather than hope.
Often, yes. Because immunotherapy and targeted therapy run over months rather than being a single procedure, the cost can frequently be spread instead of paid all at once. EMI and staged-payment options can make an otherwise daunting figure far more manageable for a family. The exact terms depend on the option you choose, so our financial counsellors walk you through what is available for your situation. The aim is simple: cost worry should never be the reason a family delays asking about the treatment that could help.
Because an honest price only exists once your drug, dose and cover are known, and those are decided by your cancer, not by a brochure. Quoting one fixed figure online would either be misleadingly low or needlessly frightening, and neither helps you plan. Instead, we explain the parts that make up the cost clearly, then give you a written estimate for your exact case during a free consultation. That estimate reflects your actual drug, your insurance or scheme, and any EMI option, so the number you see is the number that applies to you — transparent costs, with no hidden add-ons.
The fastest way is to share a few details with us — the drug that has been suggested, your PD-L1 or biomarker result, or your stage — and a CION specialist will explain the likely cost during a free 45-minute consultation. We then check your insurance, any scheme eligibility, and EMI options, and put it all into a clear written estimate. There is no commitment to start treatment, and the consultation itself is free. You can request this through the form on this page or by calling 1800 202 8726.
Browse our complete library of lung cancer guides — symptoms, types, diagnosis, stages, treatment and living with lung cancer.